Covance Introduces Dedicated Offering Designed for Biotech, Medical Device and Diagnostics Companies
January 08 2018 - 8:45AM
Business Wire
Distinctive development solutions provided
by Chiltern®, a Covance® company
LabCorp® (NYSE: LH), a leading global life sciences company,
announced today that its Covance Drug Development (Covance)
business has introduced a dedicated offering for biotech, medical
device and diagnostics companies from Chiltern®, a Covance®
company. This unique offering follows the acquisition of Chiltern,
a leading contract research organization with a track record of
engagement models that meet the specific needs of these client
segments.
“We took the opportunity presented by the acquisition and
integration of Chiltern to create an expanded, distinct and highly
customized offering specifically for our biotech, medical device
and diagnostics clients,” said John Ratliff, CEO of Covance. “Our
goal is to meet their unique needs with a bespoke sales process,
dedicated and experienced project managers, executive advocacy and
advanced collaboration technology, further customized by attentive,
personalized experience. The offering provides these clients with
seamless access to additional resources and operational
infrastructure that Covance and LabCorp bring to the table.”
Through this offering, Chiltern clients will continue to benefit
from Chiltern’s deep therapeutic expertise and extensive experience
in working with biotech, medical device and diagnostics companies.
Chiltern’s clinical trial solutions now are complemented by
Covance’s other development services, including nonclinical and
first-in-human studies, Phase I development, central laboratory
services, and regulatory and market access consulting. The offering
also provides a proprietary model for helping biotechs make the
right connection with a co-development or investment partner
through Covance MarketPlace.
“Biotech clients have asked us for solutions specifically
designed for them, along with a tailored delivery model,” said
Lewis Cameron, head of Global Clinical Development, Covance. “We
bring distinctive expertise in oncology and rare and orphan
diseases, and a deeply collaborative experience, based on
Chiltern’s successful ‘Designed Around You’ approach. The new
combined Chiltern-Covance offering will be transformational,
offering the right support and great flexibility to enable our
clients to succeed from start to end.”
About LabCorp
LabCorp (NYSE: LH), an S&P 500 company, is a leading global
life sciences company that is deeply integrated in guiding patient
care, providing comprehensive clinical laboratory and end-to-end
drug development services. With a mission to improve health and
improve lives, LabCorp delivers world-class diagnostic solutions,
brings innovative medicines to patients faster and uses technology
to improve the delivery of care. LabCorp reported net revenues of
nearly $9.5 billion for 2016. To learn more about LabCorp, visit
www.labcorp.com, and to learn more about Covance Drug Development,
visit www.covance.com.
Forward-Looking Statements
This press release contains forward-looking statements including
with respect to estimated 2017 guidance and the impact of various
factors on operating and financial results. Each of the
forward-looking statements is subject to change based on various
important factors, including without limitation, competitive
actions in the marketplace, and adverse actions of governmental and
other third-party payers. Actual results could differ materially
from those suggested by these forward-looking statements. The
Company has no obligation to provide any updates to these
forward-looking statements even if its expectations change. Further
information on potential factors that could affect operating and
financial results is included in the Company’s Form 10-K for the
year ended December 31, 2016, and subsequent Forms 10-Q, including
in each case under the heading risk factors, and in the Company’s
other filings with the SEC. The information in this press release
should be read in conjunction with a review of the Company’s
filings with the SEC including the information in the Company’s
Form 10-K for the year ended December 31, 2016, and subsequent
Forms 10-Q, under the heading MANAGEMENT’S DISCUSSION AND ANALYSIS
OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20180108006118/en/
LabCorpMedia Contact:Sue Maynard,
+1-336-436-8263Investor Contact:Scott Frommer,
+1-336-436-5076
Laboratory Corporation o... (NYSE:LH)
Historical Stock Chart
From Mar 2024 to Apr 2024
Laboratory Corporation o... (NYSE:LH)
Historical Stock Chart
From Apr 2023 to Apr 2024